

*The EUROPEAN
ASSOCIATION of
NEUROONCOLOGY*



11th MEETING

2014

October 9-12

TURIN, ITALY

Lingotto Conference Centre

FINAL PROGRAMME

www.eano.eu

HEIDELBERG

OCTOBER 13-16, 2016

12TH MEETING

See you there!



www.eano.eu

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

Congress Center Rosengarten
Mannheim/Heidelberg, Germany

TABLE OF CONTENTS



General

Committees, Boards, Organisation	2
Welcome Address	3
Overview Turin & Map	4
CME Accreditation & Future Meetings	5
Floor Plan	6

Scientific Programme

Programme at a Glance	8
Detailed Scientific Programme	
- Thursday	9
- Friday	11
- Saturday	16
- Sunday	19
Meetings	21

Scientific Information

Oral Presentations	24
Poster Viewing	24 + 25
Poster Topics	26

Corporate Satellite Symposia

Satellite Symposium 1	
Thursday, October 9, 17.30-19.00 hrs	28
Satellite Symposium 2	
Friday, October 10, 18.00-19.30 hrs	29
Satellite Symposium 3	
Saturday, October 11, 12.45-13.15 hrs	30
Satellite Symposium 4	
Saturday, October 11, 18.00-19.00 hrs	30

Information

Networking Events	33
General Information	35
Registration Fees	39
Sponsor & Exhibitor Listing	40

Printed in Austria by: ROBIDRUCK, 1200 Vienna – www.robidruck.co.at

E A N O 2 0 1 4

COMMITTEES - BOARD - ORGANISATION

EANO XI Organising Committee

Carmine Carapella (Rome)
Massimo Scerrati (Ancona)
Ugo De Paula (Rome)
Francesco Maiuri (Naples)
Roberta Rudà (Turin)
Antonio Silvani (Milan)
Andrea Pace (Rome)
Bianca Pollo (Milan)
Giuseppe Minniti (Rome)
Maurizio Iacoangeli (Ancona)
Alessandra Fabi (Roma)

EANO Board

Riccardo Soffietti, President (IT)
Michael Weller, President Elect (CH)
Wolfgang Grisold, Past President (AU)
Clemens Dirven, Treasurer (NL)
Ufuk Abacioglu, Board Member (TR)
Roger Henriksson, Board Member (SE)
Khe Hoang-Xuan, Board Member (FR)
Christine Marosi, Board Member (AU)
Geoffrey Pilkington, Board Member (UK)
Martin Taphoorn, Board Member (NL)
Wolfgang Wick, Board Member (DE)
Hanneke Zwinkels, Nurse Board Member (NL)

EANO Secretariat c/o Vienna Medical Academy

Ms. Magdalena Mara
Alser Strasse 4
1090 Vienna, Austria
T: +43 1 4051383-31
F: +43 1 4078274
E: office@eano.eu



Members of the EANO Scientific Committee (2012 - 2014)

Martin Bendszus (DE)
Anthony Chalmers (UK)
Peter Collins (UK)
Didier Frappaz (FR)
Andreas Hottinge (CH)
Florence Lefranc (BE)
Jane Fleming (IE)
Simone P. Niclou (LU)
Stefan Oberndorfer (AU)
Andrea Pace (IT)
Karl Roessler (AU)
Anja Smits (SE)
Michael Weller (CH)
Wolfgang Wick (DE)

Exhibition and Advertisements

Medizinische Ausstellungs- und
Werbegeellschaft (MAW)
Ms. Simone Weinmann, Ms. Andrea Etz
Freyung 6
1010 Vienna, Austria
T: +43 1 536 63-37
F: +43 1 535 60 16
E: maw@media.co.at

EANO XI Conference Secretariat

WMA Kongress GmbH
Ms. Therese Popp, Ms. Romana Koenig
Alser Strasse 4
1090 Vienna, Austria
T: +43 1 4051383-10
F: +43 1 4078274
E: eano2014@medacad.org

Hotel Accommodation

AIM Group International –
Aim Congress – Milan Office
Via Ripamonti, 129 - 20141 Milan, Italy
T: +39 02 566011
F: +39 02 56609043
E: eano2014.hotel@aimgroup.eu

Congress Venue EANO XI

Centro Congressi Lingotto
10126 Torino
Via Nizza 280

www.centrocongressilingotto.it

WELCOME ADDRESS

***Dear Colleague,
dear Friend,***

The Italian Association of NeuroOncology (AINO) is honoured to host the 11th EANO 2014 meeting in Turin, and welcomes you to this outstanding event in NeuroOncology. Over the last two decades there has been an explosive growth of knowledge and interest in NeuroOncology. Nowadays the proper management of NeuroOncological patients requires specific experience and training. The EANO is a multidisciplinary and multiprofessional society aiming at providing science, standards of care, education, and communication. In this regard, EANO 2014 will give you the opportunity to share the most up-to-date advances in basic science, translational and clinical research. All fields of NeuroOncology will be covered, such as biology and pathology, imaging, surgery, radiotherapy, chemotherapy, targeted therapies, supportive/palliative care and quality of life.

Turin was the first Italian capital between 1861 and 1865 and its historical importance is shown by many architectural masterpieces, like the Mole Antonelliana, which is the hallmark of the city and the Reggia di Venaria, a Royal Residency. Moreover, the Egyptian Museum is the second most important in the world.

From the beginning of the 20th century, Turin became a strong industrial centre. The Lingotto building is an example of the industrial transformation of the city. In the last years, Turin changed once again its attitude and mood, hosting the 2006 Winter Olympics Games and becoming a more international and welcoming city.

We wish you a fruitful participation at the Congress and a pleasant time in Turin.

***Roberta Rudà
Scientific Secretary
Organising Committee
EANO 2014
(on behalf of AINO)***



***Riccardo Soffietti
President, EANO
President, EANO 2014***




**EANO celebrates 20 years of continuous
medical education in NeuroOncology.
1994 - 2014**

WELCOMING ADDRESS

OVERVIEW TURIN & MAP

OVERVIEW MAP



VENUE OF EANO XI
Centro Congressi Lingotto
Via Nizza 280
10126 Torino


NETWORKING EVENT
Museo Nazionale dell'Automobile
Avv. Giovanni Agnelli
Corso Unità d'Italia 40
10126 Torino

EANO XI NETWORKING Evening
Museo Nazionale del Risorgimento Italiano di Torino
Via Accademia delle Scienze, 5
10123 Torino

DETAILED MAP – NETWORKING EVENT



DETAILED MAP – EANO XI EVENING



ACCREDITATION & FUTURE MEETINGS

CME Credits

The '11th Meeting of the European Association of NeuroOncology (EANO)' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.



The '11th Meeting of the European Association of NeuroOncology (EANO)' is designated for a maximum of (or 'for up to') **21 hours of European external CME credits**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

»Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The rules of the EACCME state that participants are kindly asked feedback (evaluation) form included in the conference bag. It can be returned to the registration desk.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Nurse Session:

Please note that the Nurse Session on Friday, October 10, 2014 from 09.00-17.30 hrs has been EONS approved.



EONS APPROVED EVENT

Future EANO Conference

**12th Meeting of the European Association of NeuroOncology
October, 13-16, 2016 – Mannheim/Heidelberg, Germany**

INFORMATION will be available online at www.eano.eu in due time.


Future WFNO Conference

**5th Quadrennial meeting of the World Federation of NeuroOncology
May 4-7, 2017 – Zurich, Switzerland**

INFORMATION will be available online at www.eano.eu in due time.

FLOOR PLAN

Turin – Lingotto Conference Centre





Scientific Programme

Programme at a Glance8

Detailed Scientific Programme

- Thursday9

- Friday11

- Saturday16

- Sunday19

Side Meetings21

Thursday, October 9, 2014

Time	Room 500	Room Londra
09.00–10.15	Educational Day: Neurological complications of cancer	09.00–16.00 Educational Day: Workshop on Laboratory-Based Science
10.15–10.35	Coffee break	09.00–10.30
10.35–12.15	Part 1: BRAIN METASTASIS	10.30–11.00 Coffee break
12.15–13.15	Part 1: BRAIN METASTASIS	11.00–12.30
13.15–14.30	Lunch break	12.30–14.00 Lunch break
14.30–15.00	Part 2: MISCELLANEOUS COMPLICATIONS	14.00–16.00
15.00–17.05	Coffee break	
17.30–19.00	Part 2: MISCELLANEOUS COMPLICATIONS	
	Satellite Symposium 1 (for more information see page XY)	

19.30 Networking Event at Museo dell'Automobile

Friday, October 10, 2014

08.45–17.30	Nurse Session - Room Madrid	
Time	Auditorium	Room 500
08.00–09.00	Meet The Experts Session 1: My personal approach to anaplastic glioma	Meet The Experts Session 2: Neurosurgery
09.00–10.30	Oral Session 1: CNS metastases and meningiomas	Oral Session 2: New developments in Radiotherapy
10.30–11.00	Oral Session 4: Malignant glioma - experimental studies	Coffee break
11.00–13.00	Oral Session 5: New developments in neurosurgery	Oral Session 6: Immunotherapy and other novel targets
13.00–14.00	Opening & Presidential Address	
14.00–14.15	Keynote Lecture	
14.15–15.00	Plenary Session: Angiogenesis inhibition: quo vadis	
15.15–16.45	Plenary Session: Advances in Brain Metastasis	
17.00–18.00	Poster Viewing with wine & cheese	
18.00–19.30	Satellite Symposium 2 (for more information see page XY)	

Saturday, October 11, 2014

Time	Auditorium	Room 500
08.00–09.00	Meet The Experts Session 1: Neuroimaging	Meet The Experts Session 3: Primary Central Nervous System Lymphomas
09.10–10.00	Special Session	
10.00–10.30	EANO Guidelines	
10.30–12.30	Oral Session 7: Neuroimaging	Coffee break
12.45–13.15	Oral Session 8: Low-grade gliomas	Oral Session 9: Quality of life and supportive care
12.30–13.30	Satellite Symposium 3 (for more information see page XY)	
13.30–15.00	Plenary Session: Novel avenues in immunotherapy for glioblastoma	
15.00–15.45	Keynote Lecture	
16.00–17.00	Plenary Session: Neurotoxicity and quality of life	
17.00–18.00	Poster Viewing with wine & cheese	
18.00–19.00	Satellite Symposium 4 (for more information see page XY)	
20.00–23.00	EANO XI Networking Evening at the Museo del Risorgimento	

Sunday, October 12, 2014

Time	Room 500	EANO General Assembly
08.00–09.00	EANO-SNO Session	
09.00–11.00	Oral Session 10: Malignant gliomas - clinical studies	
11.00–11.30	Coffee break	
11.30–12.00	Special Lecture	
12.00–13.00	Keynote Lecture	
13.00	Closing remarks and Poster awards, Closing ceremony – from President to President, Welcome to EANO XII 2016 in Heidelberg	

SCIENTIFIC PROGRAMME

Time	Room 500
	Educational Day "Neurological complications of cancer"
09.00-12.15	Part 1: BRAIN METASTASIS Chair: A. Ducati, Turin (IT); U. Ricardi, Turin (IT)
09.00-09.25	Epidemiology and prognostic factors S. Villa, Barcelona (ES)
09.25-09.50	Differential diagnosis and pitfalls on neuroimaging A. Falini, Milan (IT)
09.50-10.15	Identification and utilization of pathways involved in brain metastasis of common cancers Johan M. Kros, Rotterdam (NL)
10.15-10.35	Coffee break
10.35-11.00	Role of surgery C. Carapella, Rome (IT)
11.00-11.25	Role of stereotactic radiotherapy G. Minniti, Rome (IT)
11.25-11.50	WBRT: contemporary indications and practice B. Baumert, Bonn (DE)
11.50-12.15	Medical treatments C. Marosi, Vienna (AT)
12.15-13.15	Lunch break
13.15-17.05	Part 2: MISCELLANEOUS COMPLICATIONS Chair: F. Di Meco, Milan (IT); A. Salmaggi, Lecco (IT)
13.15-13.40	Spinal cord compression : surgery versus radiotherapy E. Moyal, Toulouse (FR)
13.40-14.05	Neoplastic meningitis R. Soffietti, Turin (IT)
14.05-14.30	Paraneoplastic syndromes B. Giometto, Treviso (IT)
14.30-15.00	Coffee break
15.00-15.25	Neurological complications of lymphoproliferative disorders U. Schlegel, Bochum (DE)
15.25-15.50	Neuromuscular complications W. Grisold, Vienna (AT)
15.50-16.15	Neurological complications in the pediatric age D. Walker, Nottingham (UK)
16.15-16.40	Venous thromboembolism and anticoagulation J. Perry, Toronto (CAN)
16.40-17.05	Supportive care: how to use corticosteroids and anti-epileptic drugs? C. Vecht, The Hague (NL)

THURSDAY, OCTOBER 9

SCIENTIFIC PROGRAMME

THURSDAY, OCTOBER 9

Time	Room Londra
09.00-16.00	Educational Day "Workshop on Laboratory-Based Science" Chair: G. Pilkington, Portsmouth (UK) ; S. P. Niclou, Luxembourg (LUX)
09.00-09.30	High throughput studies in NeuroOncology: how do I do it? M. Hegi, Lausanne (CH)
09.30-10.00	Translating high-throughput data into clinical trials A. Iavarone, New York (USA)
10.00-10.30	Targeted therapy for gliomas P. Wen, Boston (US)
10.30-11.00	Coffee break
11.00-11.30	3D in vitro modelling for glioma invasion, brain metastasis and therapeutic delivery G. Pilkington, Portsmouth (UK)
11.30-12.00	Animal models in NeuroOncology R. Bjerkvig, Bergen (NO)
12.00-12.30	Immunotherapy in experimental glioma models M. Weller, Zurich (CH)
12.30-14.00	Lunch break
14.00-14.30	Animal models of brain metastasis F. Thorsen, Bergen (NO)
14.30-15.00	Mitochondria: Integrated mutation and molecular structure studies J. McGeehan, Portsmouth (UK)
15.00-15.30	Laboratory models of tumour metabolism S. Tardito, Glasgow (UK)
15.30-16.00	Mitochondria: Novel pathways for therapeutic targeting D. Tennant, Birmingham (UK)
17.30-19.00	Satellite Symposium 1 (for more information please see page 28) Room 500
19.30	Networking Event at the Museo dell'Automobile (with Welcome by the Chairman of the School of Medicine and the Director of the City of Health and Science Hospital, Turin)

SCIENTIFIC PROGRAMME

Time	Room Madrid
08.45-17.30	Nurse Session EONS APPROVED EVENT – (simultaneous translation provided) Chair: H. Zwinkels, Den Haag (NL)
08.45-08.50	Welcome H. Zwinkels, Den Haag (NL)
08.50-09.20	The experience and needs of patients with a high-grade glioma and their family caregivers: A qualitative study W. Sterckx, Leuven (BE)
09.20-09.50	Implementation of the pathway NeuroOncology in the electronic patient file C. Nijboer, Amsterdam (NL)
09.50-10.20	State of art of NeuroOncology nursing in Piedmont, Italy: How to organize a regional network F. Salassa, Turin (IT)
	How to manage antiangiogenic treatments and clinical trials S. Panizzolo, Turin (IT)
10.20-11.00	Coffee break
11.00-11.30	Patient/spouse relationship and their different views of the world..... P. Salander, Umeå (SE)
11.30-12.00	Privacy-solidarity conflict: the communication between doctor, patient and their caregiver C. Y. Finocchiaro, Milan (IT)
12.00-12.30	Coping strategies for patients/caregivers and the neurocognitive changes of patients in Turin context A. Malabaila, Turin (IT)
12.30-13.30	Lunch break
13.30-14.00	Do's and don'ts in research from a research nurse perspective E. Gortmaker, The Hague (NL)
14.00-14.30	Needs and preferences for supportive and rehabilitative interventions among patients with high grade gliomas and their relatives – a mixed methods study K. Pill, Copenhagen (DK)
14.30-15.00	High grade glioma and a new reality: long-term survivorship? M. Lovely, San Francisco (US)
15.00-15.30	Coffee break
15.30-16.00	Awake craniotomy in low grade glioma F. Kloet, Den Haag (NL)
16.00-16.30	The role of physiotherapy in the treatment of patients with brain tumors in the hospital setting H. Radford, Den Haag (NL)
16.30-17.00	Epilepsy in the end of life phase: epidemiology and management J. Koekoek, Amsterdam/Den Haag (NL)
17.00-17.30	"Treatment at end of life: how to share the decision process involving patients, caregivers and health professionals" L. Guariglia, Rome (IT)
17.30-18.00	Discussion



FRIDAY, OCTOBER 10

SCIENTIFIC PROGRAMME

FRIDAY, OCTOBER 10

Time	Auditorium	Room 500	Room Londra
08.00-09.00	Meet The Experts Session 1: My personal approach to anaplastic glioma Chair: M. Hegi, Lausanne (CH) The diagnostic perspective G. Reifenberger, Dusseldorf (DE) A therapeutic algorithm from Paris M. Sanson, Paris (FR) A therapeutic algorithm from Heidelberg W. Wick, Heidelberg (DE)	Meet The Experts Session 2: Neurosurgery Chair: C. Dirven, Rotterdam (NL) Intraoperative monitoring L. Bello, Milan (IT) Fluorescence-guided resections: update 2014 W. Stummer, Münster (DE) Intra-operative imaging Z. Ram, Tel Aviv (IS)	Meet The Experts Session 3: NeuroOncology Chair: F. Giangaspero, Rome (IT) Adolescents and young adults with cancer: why do they require specific care? A. Ferrari, Milan (IT) Medulloblastomas: from pediatric experience to adult care D. Frappaz, Lyon (FR) Intracranial germ cell tumors: the chance to provide common care in adolescents and young adults G. Calaminus, Munster (DE)
09.00-10.30	Oral Session 1: CNS metastases and meningiomas Chair: S. Villa, Barcelona (ES), M. Preusser, Vienna (AU)	Oral Session 2: New developments in Radiotherapy Chair: S. Errige, Edinburgh (UK), E. Moyal, Toulouse (FR)	Oral Session 3: Neurotoxicity and neuroprotection Chair: W. Grisold, Vienna (AU), R. Grant, Edinburgh (UK)
09.00-09.12	01.01 Estimation of the incidence of brain metastases and patterns of care in the Netherlands Robert J.J.M. Kwakman , P.M. Jeene, E.M.T. Dieleman, L.J.A. Stalpers; Amsterdam (NL)	02.01 Radiation Therapy Dose Painting utilizing FET and FDG PET in the management of high grade glioma Michael Back , D. Bailey, G. Schembri, M. Kastelan, E. Bailey, H. Wheeler; Sydney NSW (AU)	03.01 Progression of carotid intima media thickness after radiotherapy: a prospective cohort study Joyce Wilbers , L. Dorresteyn, R. Haast, F. Hoebbers, W. Boogerd, E. van Werkhoven, H. Hansen, C. de Korte, A. Kappelle, E. van Dijk; Nijmegen (NL)
09.12-09.24	01.02 New Graded prognostic index for Renal Cell Carcinoma patients with brain metastases (RCCBM) Manmeet S. Ahluwalia , V. Alva-Venur, P. Elson, G.H.J. Stevens; Cleveland (US)	02.02 Role of an integrated imaging for target volume definition and radiotherapy planning in patients with diagnosed high grade glioma Pierina Navarra , F. Pessina, S. Tomatis, P. Mancosu, A. Ascolese, E. Lopci, A. Bizzi, E. Clerici, L. Bello, M. Scorsetti; Milano (IT)	03.02 Radiation-induced leukoencephalopathy is a definite type of small vessel disease. Neuropsychological and MRI description in 40 patients Flavie Bompaire , M. Lahutte, D. Psimaras, M. Sallansonnet-Froment, T. De Greslan, H. Taillia, J. Renard, S. Alamovitch, K. Hoang-Xuan, D. Ricard; Paris (FR)
09.24-09.36	01.03 Density of tumor infiltrating lymphocytes correlates with brain edema and overall survival in brain metastases Anna S. Berghoff , A. Wöhrer, M. Hackl, J. Pichler, M. Hutterer, G. Widhalm, K. Dieckmann, D. Prayer, J.A. Hainfellner, M. Preusser; Vienna (AT)	02.03 Target delineation in glioblastoma: is preoperative automatic comparable to expert based segmentation? Alessia Pica , D. Terribilini, N. Porz, M. Reyes, J. Slotboom, R. Wiest, S. Bauer; Bern (CH)	03.03 The spectrum of late paroxysmal neurological syndromes after brain irradiation Giulia Berzero , Pavia NeuroOncology Group, F. Ducray, B. Giometto, A. Silvani, A. Salmaggi, M. Eoli, G. Finocchiaro, A. Vidiri, A. Pace; Pavia (IT)
09.36-09.48	01.04 Role of Aquaporin4 in human brain metastases: study of 60 cases Bianca Pollo , S. Mazzetti, M. Patané, C. Calatozzolo, F. Cacciatore, A. Silvani, F. Di Meco, R. Nunziata; Milano (IT)	02.04 Treatment with OMX-4.80, a tumor-penetrating tunable oxygen carrier, reduces tumor hypoxia and dramatically enhances radiation therapy in intracranial models of glioblastoma A. Krtolica, N. Le Moan, L. Serwer, Y. Yoshida, T. Ozawa, N. Butowski, D. James, Stephen Cary ; San Carlos (US)	03.04 Cognitive and structural brain changes associated with prophylactic cranial irradiation in long term small cell lung cancer survivors Marta Simó , L. Vaquero, P. Ripollés, J. Jové, R. Fuentes, F. Cardenal, A. Rodríguez-Fornells, J. Bruna; Barcelona (ES)

SCIENTIFIC PROGRAMME

Time	Auditorium	Room 500	Room Londra
09.48-10.00	01.05 Axitinib, a selective VEGFR-1,-2,-3 tyrosine kinase inhibitor, inhibits tumor growth and increases infiltration of immune cells in an intracranial melanoma mouse model Stephanie Du Four , S.K. Maenhout, S.P. Niclou, K. Thielemans, B. Neyns, J.L. Aerts; Brussel (BE)	02.05 May we routinely spare hippocampal region in primary central nervous system lymphoma during whole brain radiotherapy? B. Diletto , D. Marchesano, Silvia Chiesa , A. Alitto, S. Gaudino, M. Ferro, C. Mazzarella, C. Colosimo, V. Valentini, M. Balducci; Rome (IT)	03.05 Chemotherapy-induced peripheral neurotoxicity (CIPN): the impact of sensory ataxia on patient reported assessment of motor impairment Paola Alberti , CI-PeriNomS Group; Monza (IT)
10.00-10.12	01.06 Novel markers of meningioma aggressiveness. A study of meningioma versus peritumoral nervous tissue Samanta Mazzetti , C. Calatozzolo, M. Patanè, M. Farinotti, R. Nunziata, S. Lodrini, P. Bianca; Milano (IT)	02.06 Use of MRI fusion for CT based intracranial stereotactic radiosurgery Hale B. Caglar , A. Yildirim Altinok, E. Kucukmorkoc, H. Acar, N. Kucuk; Istanbul (TR)	03.06 The effect of acetyl-L-carnitine in reducing the taxanes induced neuropathy Mahmoud A. Ellithy , R.R. Ghali, W.R. Elghamry, S. Eltaeb, I.M. El wakeel, K. Elhoseiny; Cairo (EG)
10.12-10.24	01.07 Intracranial hemangiopericytomas lack typical cytogenetic and epigenetic features of meningiomas: a comprehensive molecular genetic study D. Kraemer , S.I. Orie, Ralf Ketter , J. Oertel, S. Urbschat; Homburg/Saar (DE)	02.07 First 100 Vestibular Schwannomas treated with Gamma Knife in Spain: long-term outcome Pablo de Andrés , A. Lo Presti, M.E. Kusak, N. Martínez, J.M. de Campos, R. Martínez; Madrid (ES)	03.07 Quick, non invasive and quantitative evaluation of small fiber neuropathy in patients receiving chemotherapy Mehdi Saad , C. Tafany, D. Ricard; Paris (FR)
10.30-11.00	Coffee Break		
11.00-13.00	Oral Session 4: Malignant glioma - experimental studies Chair: K. Aldape, Houston (US), R. Bjerkvig, Bergen (NO)	Oral Session 5: New developments in neurosurgery Chair: C. Dirven, Rotterdam (NL), L. Bello, Milano (IT)	Oral Session 6: Immunotherapy and other novel targets Chair: M. Platten, Heidelberg (DE), P. Wen, Boston (US)
11.00-11.12	04.01 Distinct functional roles of wild-type EGFR and its mutant EGFRVIII in glioblastoma development Hrvoje Miletic , G.V. Rosland, E. Eskilsson, K. Vaelk, O. Keunen, R. Jahedi, F. Azuaje, D. Stieber, S. Foerster, C. Ritter; Bergen (NO)	05.01 Standards and advanced testing for intraoperative language and cognitive mapping Alessandro Comi , M. Riva, A. Casarotti, E. Fava, F. Pessina, C. Papagno, L. Bello; Milano (IT)	06.01 Targeting the immune checkpoint network with miR-138 exerts therapeutic efficacy in murine models of glioma Amy Heimberger , J. Wei, E. Nduom, L. Kong, C. Ivan, G.N. Fuller, M.R. Gilbert, C.A. Conrad, G.A. Calin; Houston (US)
11.12-11.24	04.02 Exosomal miRNA from glioma-associated mesenchymal stem cells promote glioma growth and progression Javier M. Figueroa , T. Shahar, A. Hossain, J. Gumin, F. Lang; Houston (US)	05.02 Cortical and Subcortical language mapping with HighFrequency (HF) stimulation: feasibility and clinical results Marco Riva , A. Comi, E. Fava, T. Alfiero, A. Casarotti, F. Pessina, L. Bello; Milano (IT)	06.02 Analysis of PD1 and PD-L1 expression in glioblastoma Anna S. Berghoff , B. Kiesel, G. Widhalm, A. Wöhrer, K. Dieckmann, M. Filipits, C. Marosi, J.A. Hainfellner, M. Preusser, W. Wick; Vienna (AT)
11.24-11.36	04.03 Glioblastoma stimulated angiogenesis is mediated by MMP-3 activated MMP-1 via brain endothelial cell associated Protease Activated Receptor 1 (PAR1) and is enhanced under hypoxic conditions. S. Briggs , K. Stephenson, J. Holliday, R. Peckham, D. Arthur, M. Papanikolaou, A. Butt, A. Pickford, G. Pilkington, Helen L. Fillmore ; Portsmouth (UK)	05.03 Application of laser speckle to the identification of functional brain areas in awake surgery Jean-Michel Lemée , P. Abraham, A. Ter-Minassian, P. Menei; Angers (FR)	06.03 A phase II trial of autologous dendritic cells vaccination and radio-chemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients: preliminary clinical results of the «DEND/GBM» trial- Jaime Gállego Pérez-Laraya , S. Tejada-Solís, A. L de Cerio, S. Inogés, J. Espinós, R. Díez-Valle; Pamplona (ES)

FRIDAY, OCTOBER 10

SCIENTIFIC PROGRAMME

FRIDAY, OCTOBER 10

Time	Auditorium	Room 500	Room Londra
11.36-11.48	04.04 'From the core to beyond the margin': a genomic picture of glioblastoma intratumor heterogeneity Marc Aubry , M. de Tayrac, A. Etcheverry, A. Clavreul, S. Saikali, P. Menei, J. Mosser; Rennes (FR)	05.04 Preliminary results of the GALA-5 study: an evaluation of the tolerability and feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with carmustine wafers (Gliadel) in the surgical management of primary glioblastoma Colin Watts , K. Wanek, P. Smith, N. Counsell, GALA-5 Clinical Trial Consortium; Cambridge (UK)	06.04 Granulocytic myeloid-derived cells obtained from blood mainly suppress T-cell proliferation in patients with glioblastoma Oliver M. Grauer , J. Wölfer, M. Hasselblatt, D. Dubinski, U. Bogdahn, W. Stummer, H. Wiendl; Münster (DE)
11.48-12.00	04.05 Genetic diversity and intra-tumor heterogeneity in human glioblastoma Sara G.M. Piccirillo , I. Spiteri, A. Sottoriva, A. Touloumis, P. Collins, C. Curtis, J. Marioni, S. Tavaré, C. Watts; Cambridge (UK)	05.05 Fluorescein-guided removal of high-grade gliomas with a dedicated filter on the surgical microscope: preliminary results of the FLUOGLIO study Francesco Acerbi , M. Broggi, C. Cavallo, E. Anghileri, M. Eoli, M. Schiariti, E. La Corte, B. Pollo, C. Boffano, P. Ferroli; Milano (IT)	06.05 ErbB2/HER2-specific natural killer cells for adoptive immunotherapy of glioblastoma Michael C. Burger , C. Zhang, L. Jennewein, K. Schönfeld, S. Genßler, M. Grez, T. Tonn, M. Mittelbronn, J.P. Steinbach, W.S. Wels; Frankfurt (DE)
12.00-12.12	04.06 Analysis of RAF proteins in malignant gliomas Carsten Hagemann , J. Gloger, A.F. Kessler, T. Linsenmann, G.H. Vince, R. Ernestus, M. Löhr; Würzburg (DE)	05.06 Cystic craniopharyngiomas: microsurgical or stereotactic treatment? Walter Rachinger , M. Kunz, N. Thon, J.C. Tonn, F.W. Kreth; Munich (DE)	06.06 Peripheral T cell responses in glioblastoma patients are associated with an improved survival Christel C. Herold-Mende , J. Mossemann, C. Jungk, R. Ahmadi, A. Unterberg, D. Capper, A. vonDeimling, P. Beckhove; Heidelberg (DE)
12.12-12.24	04.07 A novel Polycomb feed forward loop in glioblastoma multiforme Silvia Marino , D. Ceric, B. Ricci, M. Barnes; London (UK)	05.07 - The impact of neuronavigation and intraoperative high-field MRI on surgery of gangliogliomas in patients with drug resistant epilepsy Karl Roessler , B. Sommer, C. Wimmer, H.M. Hamer, I. Blümcke, M. Buchfelder; Erlangen (DE)	06.07 FGFR3-TACC3 and EGFR-SEPT14 gene fusions in adult gliomas Anna Luisa Di Stefano , M. Labussiere, V. Frattini, A. Fucci, B. Boisselier, Y. Schmitt, K. Mokhtari, A. Lasorella, A. Iavarone, M. Sanson; Paris (FR)
12.24-12.36	04.08 AGI5198, an inhibitor of IDH1R132H, protects IDH1R132H HCT116 cells against irradiation Remco J. Molenaar , D. Dimitrakopoulou, J. Stap, F.E. Bleeker, C.J.F. Van Noorden; Amsterdam (NL)	05.08 Intra-operative neurophysiological monitoring and small craniotomies: results in a consecutive series of 85 patients with brain tumors Giorgio Carrabba , G. Bertani, F. Cogiamanian, G. Ardolino, A. Di Cristofori, B. Zarino, M. Locatelli, S. Barbieri, M. Caroli, P. Rampini; Milan (IT)	06.08 Combined analysis of TERT, EGFR and IDH status define distinct prognostic classes of glioblastoma M. Labussiere , B. Boisselier, K. Mokhtari, A. Di Stefano, A. Rahimian, O. Saulnier, R. Pattera, G. Finocchiaro, Y. Marie, Marc Sanson ; Paris (FR)
12.36-12.48	04.09 In situ metabolic profiling sheds light on oxidative stress pathways in IDH1 mutant oligodendroglioma F. Fack , G. Hochart, A. Oudin, O. Keunen, W.P. Leenders, E. Gottlieb, R. Bjerkvig, J. Stauber, Simone P. Niclou ; Luxembourg, Luxembourg	05.09 Ventricular high grade glioma: neuroendoscopy and adjuvant therapy Piero A. Oppido , F. Cattani, C.M. Carapella, V. Villani; Roma (IT)	06.09 Prostaglandin E receptor-4 activation regulates tryptophan metabolism in human malignant gliomas Katharina Ochs , M. Ott, K.J. Rauschenbach, F. Sahm, C.A. Opitz, A. von Deimling, W. Wick, M. Platten; Heidelberg (DE)

SCIENTIFIC PROGRAMME

Time	Auditorium	Room 500	Room Londra
12.48-13.00	04.10 CNS stem cell specific tumorigenesis reveals lineage relationship between experimental and human gliomas and a dominance of glial signatures during tumour propagation in vitro Sebastian Brandner , N. Henriquez, A. Benedykcinska, N. Li, J. Lau, K. Sidlauskas; London (UK)	05.10 5-ALA fluorescence guided resection of hemangioblastomas - Is it useful with conventional surgical tools? Jose M. De Campos , L. Sainz, A. Lo Presti, M. Ramirez, D. Aguirre, C. Ordoñez, L. Daoud; Madrid (ES)	06.10 Glioma cell VEGFR-2 expression impairs chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma Markus Weiler , T. Kessler, F. Sahm, J. Blaes, M. Osswald, D. Milford, S. Urban, C. Ruiz de Almodóvar, S. Heiland, W. Wick; Heidelberg (DE)
13.00-14.00	Lunch Break		
14.00-14.15	Presidential Address Riccardo Soffietti, President EANO		
14.15-15.00	Keynote Lecture Chair: M. Scerrati, Ancona (IT) Multimodal imaging for improved outcome in glioma surgery and management J.C. Tonn, Munich (DE)		
15.15-16.45	Plenary Session: Angiogenesis inhibition: quo vadis Chair: G. Pilkington, Portsmouth (UK); W. Wick, Heidelberg (DE) AVAGlio and RTOG 0825 in perspective M. J. van den Bent, Rotterdam (NL) Overcoming bevacizumab failure D. Reardon, Boston (US) Escape strategies S. P. Niclou, Luxembourg (LUX)	Plenary Session: Advances in Brain Metastasis Chair: A. Chalmers, Glasgow (UK); U. Abacioglu, Istanbul (TR) Biological principles: new targets for improved therapies F. Winkler, Heidelberg (DE) Endpoints in brain metastasis trials R. Soffietti, Turin (IT) Targeted therapy M. Preusser, Vienna (AT)	
17.00-18.00	Poster viewing 1 - with wine & cheese P01 Cell biology and signalling P01.01-23 P02 Immunology and immunotherapy P02.01-07 P03 In vitro / in vivo models P03.01-09 P04 Molecular markers P04.01-26 P05 Pediatric brain tumours P05.01-08 P06 Meningiomas P06.01-16 P07 Spinal cord tumours P07.01-06 P08 Brain and leptomeningeal metastases P08.01-28 P11 Primary central nervous system lymphoma (PCNSL) P11.01-10 P12 New developments in surgery P12.01-14 P13 New developments in radiotherapy P13.01-26		
18.00-19.30	Satellite Symposium 2 (for more information please see page 29)		Room 500

FRIDAY, OCTOBER 10

SCIENTIFIC PROGRAMME

SATURDAY, OCTOBER 11

Time	Auditorium	Room 500	Room Londra
08.00-09.00	Meet The Experts Session 1: Neuroimaging Chair: F. Dhermain, Paris (FR) Innovative MRI techniques Alan Jackson, Manchester (UK) PET: Old and new tracers U. Roelcke, Aarau (CH) IDH spectroscopy S. Heiland, Heidelberg (DE)	Meet The Experts Session 2: Epilepsy in low-grade glioma Chair: J. Heimans, Amsterdam (NL) Basic mechanisms J. Uhm, Rochester (US) The impact of surgery H. Duffau, Montpellier (FR) Radiotherapy and chemotherapy: new options? R. Rudà, Turin (IT)	Meet The Experts Session 3: Primary Central Nervous System Lymphomas Chair: A. Hottinger, Lausanne (CH) Molecular pathogenesis of PCNSL M. Deckert, Cologne (DE) Treating young patients with curative intent A. Ferreri, Milan (IT) Elderly K. Hoang-Xuan, Paris (FR)
09.10-10.00	Special Session Chair: R. Soffietti, Turin (IT); M. Weller, Zurich (CH)		
09.10-09.34	Special Lecture: S1.01 Novel developments in the diagnosis of human brain tumors - the potential of classification by methylation analysis A. von Deimling, Heidelberg (DE)		
09.34-09.46	ASNO award: S1.02 Sublethal irradiation enhances invasiveness of malignant glioma cells; implications for radiotherapy of human glioblastoma Shin Jung , J. Pei, H. Hwa Ryu, I.H. Park, M. Wen, W.Y. Jang, T.Y. Jung, K.S. Moon, I.Y. Kim; Jeollanam-do (KR)		
09.46-09.58	SNO award: S1.03 Glioblastoma subtypes defined by quantitative imaging map to different canonical signaling pathways Oliver Gevaert , H. Itakura, A. Achrol, J. Loya, L. Mitchell, T. Azad, S. Echegaray, K. Yeom, S. Napel, G. Harsh; Stanford (US)		
10.00-10.30	EANO Guidelines Chair: R. Soffietti, Turin (IT); M. Weller, Zurich (CH)		
10.00-10.05	Review of EANO initiatives up to 2014 R. Soffietti, Turin (IT)		
10.05-10.15	EANO Guidelines on Malignant Glioma M. Weller, Zurich (CH)		
10.15-10.25	EANO Guidelines on Primary CNS Lymphoma K. Hoang-Xuan, Paris (FR)		
10.25-10.30	EANO Guideline Strategy for the Future M. Weller, Zurich (CH)		
10.00-10.30	Coffee Break		
10.30-12.30-11.00-11.12	Oral Session 7: Neuroimaging Chair: S. Chang, San Francisco (US), A. Jackson, Manchester (UK) 07.01 Response assessment in NeuroOncology (RANO) criteria for brain metastases Patrick Y. Wen , E.Q. Lee, M. Van Den Bent, R. Soffietti, M. Bendszus, M. Mehta, B. Baumert, M. Vogelbaum, S.M. Chang, N.U. Lin; Boston (US)	Oral Session 8: Low-grade gliomas Chair: B. Baumert, Bonn (DE), C. Watts, Cambridge (UK) 08.01 Pre-operative chemotherapy as a new strategy in treating low grade gliomas in eloquent areas Luca Bertero , R. Rudà, A. Castellano, E. Trevisan, M. Magistrello, A. Pellerino, M. Riva, A. Falini, L. Bello, R. Soffietti; Turin (IT)	Oral Session 9: Quality of life and supportive care Chair: C. Marosi, Vienna (AU), J. Reijneveld, Amsterdam (NE) 09.01 The role of gender in CNS tumour incidence and survival R. Mathew, S. Alli, J. Hayes, R. Parslow, J Goodden , P. Chumas; Leeds (UK)

SCIENTIFIC PROGRAMME

Time	Auditorium	Room 500	Room Londra
11.12-11.24	07.02 Radiosurgery and brain metastases: adequate sequence of brain MRI can significantly change the intracranial disease staging Silvia Scoccianti , D. Greto, L. Bordi, P. Bono, G. Pecchioli, M. Casati, E. Vanzi, A. Compagnucci, D. Gadda, L. Livi; Firenze (IT)	08.02 Monitoring of treatment response in IDH-mutant gliomas with in-vivo 3D magnetic resonance spectroscopy D.P. Cahill, Franziska Loebel , W. Bogner, M. Marjanska, E. Gerstner, T. Batchelor, B.R. Rosen, A. Chi, O.C. Andronesi; Boston (US)	09.02 Needs of informal caregivers of primary malignant brain tumor patients in the United States and the Netherlands: an international comparison Florien W. Boele , M. Klein, T.S. Armstrong, J.C. Reijneveld, T.J. Postma, M.J.B. Taphoorn, N.K. Aaronson, J.J. Heimans, P.R. Sherwood; Amsterdam (NL)
11.24-11.36	07.03 IDH-1 mutated glioblastomas have a less invasive phenotype than IDH-1 wild type glioblastomas: a diffusion tensor imaging study Stephen J. Price , N.R. Boonzaier, V. Lupson, T. Larkin; Cambridge (UK)	08.03 Low grade diffuse astrocytoma: Validation of imaging prognostic factors to anaplastic transformation Cristina Izquierdo , C. Majos, M. Simó, A. Lucas, M. Macià, G. Plans, M. Gil, R. Velasco, J. Bruna; Barcelona (ES)	09.03 Brain tumors in Sweden: data from a population based registry 1999-2012 Thomas Asklund , A. Malmström, M. Bergqvist, O. Björ, R. Henriksson; Umeå, Sweden
11.36-11.48	07.04 DCE-MRI discriminates between responder and non-responder in recurrent high-grade glioma patients undergoing anti-angiogenic treatment Martha Nowosielski , C. Kremser, M. Schocke, E. Gizewski, S. Iglseder, A. Muigg, C. Freyschlag, G. Stockhammer, M. Hutterer; Innsbruck (AT)	08.04 Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults G. Reyes-Botero, Florence Laigle-Donadey , K. Mokhtari, N. Martin-Duverneuil, J.Y. Delattre; Paris (FR)	09.04 High grade gliomas and caregivers' psychological burden Alessandra Petrucci , C.Y. Finocchiaro, G. Vistalli, A. Botturi, I. Milanese, A. Silvani, E. Lamperti; Milano (IT)
11.48-12.00	07.05 Differentiation of local recurrent brain metastasis from radiation-induced changes using O-(2-[18F]fluoroethyl)-L-tyrosine PET Norbert Galldiks , M.I. Ruge, C. Hamisch, G. Stoffels, G. Ceccon, M. Rapp, M. Sabel, K. Langen; Cologne (DE)	08.05 Structural characterization of low grade gliomas by integration of MR, Ultrasound and PET imaging Marco Riva , E. Lopci, F. Raneri, T. Alfiero, F. Pessina, A. Castellano, A. Falini, A. Chiti, L. Bello; Milano (IT)	09.05 Cognitive functioning, health-related quality of life and survival after stereotactic radiotherapy in patients with brain metastases Esther J.J. Habets , L. Dirven, R. Wiggenraad, H. Zwinkels, G.J. Lycklama à Nijeholt, M.J.B. Taphoorn; The Hague (NL)
12.00-12.12	07.06 Magnetic nanoparticles conjugated to a recombinant heat shock protein Hsp70 for targeting experimental glioblastoma Maxim Shevtsov , B. Nikolaev, L. Yakovleva, Y. Marchenko, A. Dobrodumov, B. Margulis, A. Ischenko, W. Khachatryan, I. Guzhova; St.Petersburg, (RUS)	08.06 ATRX and TERT expression in relapsing low grade glioma Chiara Calatozzolo , M. Patané, S. Mazzetti, M. Eoli, M. Farinotti, R. Nunziata, G. Finocchiaro, B. Pollo; Milano (IT)	09.06 Prognostic relevance and oncogenic correlates of epilepsy in glioblastoma patients Sharon Berendsen , J. Kroonen, T. Seute, T. Snijders, M.L.D. Broekman, W.G.M. Spliet, M. Willems, M. Artesi, V. Bours, P.A. Robe; Utrecht (NL)
12.12-12.24	07.07 PET imaging of brain gliomas with C-11 acetate: comparison with F-18 FDG PET Jong Hee Chang , E. Kim, S. Kang, S. Kim, M. Yun; Seoul, (KR)	08.07 Histology, localisation, treatment and outcome of 339 consecutive children and adolescents with Low Grade Gliomas treated at the Medical University of Vienna between 1993 and 2012 Irene Slavic , M. Chocholous, A. Woehrer, R. Heumesser, A. Azizi, C. Haberler, A. Peyrl, C. Dorfer, K. Dieckmann, T. Czech; Vienna (AT)	09.07 Cognitive improvement after meningioma surgery I. Meskal, K. Gehring, S. van der Linden, Geert-Jan Rutten , M. Sitskoorn; Tilburg (NL)
12.24-12.36	07.08 One-stop shopping in brain tumor imaging: initial experience with PET/MR for simultaneous evaluation of tumor metabolism, structure and blood volume using [18F]-fluor-ethyl-tyrosine PET and DSC-MRI Otto M. Henriksen , V.A. Larsen, A. Muhic, A.E. Hansen, H.B.W. Larsson, H.S. Poulsen, I. Law; Copenhagen, (DK)	08.08 CIC mutation is a poor prognosis factor in 1p19q codeleted gliomas, associated to an up-regulation of proliferation pathways Vincent Gleize , A. Alentorn, L. Connen de Kérillis, M. Labussière, S. Mangesius, F. Ducray, K. Mokhtari, C. Villa, M. Sanson; Paris (FR)	09.08 End of life care in high-grade glioma patients in three European countries: a comparative study Johan A.F. Koekkoek , L. Dirven, J.C. Reijneveld, H.R.W. Pasman, S. McNamara, W. Grisold, G. Stockhammer, C. Marosi, M.J.B. Taphoorn, J.J. Heimans; Amsterdam (NL)

SATURDAY, OCTOBER 11

SCIENTIFIC PROGRAMME

SATURDAY, OCTOBER 11

Time	Auditorium	Room 500	Room Londra
12.36-12.48	07.09 [68Ga]-DOTATATE-PET imaging predicts somatostatin receptor II expression in meningiomas Walter Rachinger , V. Stöcklein, A.R. Haug, U. Schüller, C. Schichor, N. Thon, J.C. Tonn; Munich (DE)	08.09 The Leeds low grade glioma service 2010-13 <i>R. Mathew, S. Spink, D. O'Hara, C. Loughrey, E. Wright, A. Chakrabarty, T. Patankar, J. MacMullen-Price, John Goodden, P. Chumas;</i> Leeds (UK)	09.09 Efficacy and tolerability of lacosamide in patients with glioma: a prospective study Alessia Pellerino , L. Bertero, E. Trevisan, M. Magistrello, R. Soffietti, R. Rudà; Turin (IT)
12.48-13.00	07.10 Correlation of pre-operative language fMRI with intra-operative direct cortical stimulation findings in glioma surgery identifies potential false positive fMRI activations with conventional analysis David J. Coope , K. Karabatsou, S. Green, G. Wall, J. Bambrough; Manchester (UK)	08.10 A model for research initiatives for rare cancers: the collaborative ependymoma research network (CERN) Terri S. Armstrong , K. Aldape, A. Gajjar, C. Haynes, D. Hirakawa, R. Gilbertson, M.R. Gilbert; Houston (US)	09.10 Anti-epileptic treatment in glioma, a Norwegian population-based study Kristin M. Knudsen-Baas , T.B. Johannesen, A. Engeland, B.A. Engelsen, A.M. Storstein, J.F. Owe; Bergen (NO)
12.45-13.15	Satellite Symposium 3 (for more information please see page 30)		Room 500
12.30-13.00	Lunch Break		
13.30-15.00	Plenary Session: Novel avenues in immunotherapy for glioblastoma Chair: G. Finocchiaro, Milan (IT); R. Henriksson, Stockholm (SE) Is there a role for ipilimumab and PD-1/PD ligand modulation? M. Gilbert, Houston (US) IDH1R132H as an immunotherapeutic target in glioma M. Platten, Heidelberg (DE) EGFRvIII as an immunotarget in glioblastoma M. Weller, Zurich, (CH)	Plenary Session: Neurotoxicity and quality of life Chair: S. Oberndorfer, Vienna (AT); M. Taphoorn, The Hague (NL) How to best deal with quality of life evaluation in brain tumors? M. Taphoorn, The Hague (NL) Cognitive assessment M. Klein, Amsterdam (NL) End of life decisions A. Pace, Rome (IT)	
15.00-15.45	Keynote Lecture Chair: A. van Deimling, Heidelberg (GER) Molecular genetics for the next WHO classification K. Aldape, Houston (US)		
16.00-17.00			EANO General Assembly
17.00-18.00	Poster viewing 2 - with wine & cheese P09 Neurotoxicity and neuroprotection..... P09.01-04 P10 Paraneoplastic neurological syndromes P10.01-03 P14 Epidemiology P14.01-07 P15 Quality of life P15.01-17 P16 Neuroimaging of brain tumours..... P16.01-35 P17 Glioblastoma and anaplastic gliomas P17.01-95 P18 Supportive and palliative care..... P18.01-10		
18.00-19.00	Satellite Symposium 4 (for more information please see page 30)		Room 500
20.00-23.00	EANO XI Networking Evening at the Museo del Risorgimento		

SCIENTIFIC PROGRAMME

Time	Room 500
08.00-09.00	EANO-SNO Session Chair: M. Gilbert, Houston (US); R. Soffietti, Turin (IT) Lessons from the integrin inhibition in brain tumors R. Stupp, Zurich (CH) Update on RANO criteria S. Chang, San Francisco (US)
09.00-11.00	Oral Session 10: Malignant gliomas - clinical studies Chair: M. Gilbert, Houston (US), R. Stupp, Zurich (SW)
09.00-09.12	O10.01 Prognostic and predictive biomarker-based subgroups in the NOA-04 trial Wolfgang Wick , D. Capper, M. Sill, V. Hovestadt, S.M. Pfister, M. Platten, G. Reifenberger, A. von Deimling, M. Weller, B. Wiestler; Heidelberg (DE)
09.12-09.24	O10.02 Mitotic index, microvascular proliferation and necrosis define three groups of 1p/19q co-deleted anaplastic oligodendrogliomas associated with different genomic alterations Dominique Figarella-Branger , K. Mokhtari, C. Dehais, A. Jouvet, E. Uro-Coste, C. Colin, C. Carpentier, F. Ducray, A. Idhah, French POLA Network; Marseille (FR)
09.24-09.36	O10.03 Physiological and biological responses of human glioblastomas to bevacizumab treatment assessed by metabolomic flux analysis F. Fack, H. Espedal, O. Keunen, A. Golebiewska, N. Obad, L. Zheng, E. Gotlieb, P. Harter, S. P. Niclou, Rolf Bjerkvig ; Bergen (NO)
09.36-09.48	O10.04 The randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan vs standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients: final survival results and quality of life Ulrich Herrlinger , N. Schäfer, J.P. Steinbach, A. Weyerbrock, P. Hau, R. Goldbrunner, B. Leutgeb, H. Urbach, W. Stummer, M. Glas; Bonn (DE)
09.48-10.00	O10.05 Final analysis of the BELOB trial (A randomized phase II study on bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma) and first radiology review results W. Taal, H.M. Oosterkamp*, A.M.E. Walenkamp*, H.J. Dubbink*, L.V. Beerepoot, M. Hanse, J. Buter, A. Honkoop, D. Boerman, F.Y.F. Vos, W.N.M. Dinjens, R.H. Enting, M.J.B. Taphoorn, F.W.P.J. van den Berkmoortel, R. Jansen, D. Brandsma, J.E. Bromberg, I. van Heuvel, R.M. Vernhout, B. van der Holt, Martin J. van den Bent ; Rotterdam (NL)
10.00-10.12	O10.06 A phase II study of AINO (Italian Association of NeuroOncology) on bevacizumab and fotemustine for recurrent glioblastoma: outcome, patterns of relapse and salvage treatments. Elisa Trevisan , L. Bertero, P. Cassoni, I. Morra, F. Pasqualetti, I. Lolli, A. Castiglione, G. Ciccone, R. Rudà, R. Soffietti; Turin (IT)

SUNDAY, OCTOBER 12

SCIENTIFIC PROGRAMME

SUNDAY, OCTOBER 12

Time	Room 500
10.12-10.24	O10.07 Randomized phase II study of axitinib vs. standard of care in patients with recurrent glioblastoma Johnny Duerinck , S. Du Four, F. Bouttens, V. Verschaeve, H. Everaert, S. De Raedt, A. Van Binst, B. Neyns; Jette (BE)
10.24-10.36	O10.08 High G-protein-coupled receptors 65 (GPR65) expression predicts a poorer surgical outcome of glioblastoma patients Tao Xu , H. Wang, Y. Yan, R. Qin, Y. Jiang, Y. Lu, W. Li, C. Xia, J. Chen; Shanghai, China
10.36-10.48	O10.09 Reduction in neutrophil-lymphocyte ratio during initial concurrent chemoradiotherapy is prognostic for survival of glioblastoma patients Matthew T. Mason , M.G. McNamara, M.T. Tieu, Z. Lwin, B.A. Millar, C. Menard, N. Laperriere, M. Milosevic, W.P. Mason, C. Chung; Toronto (CA)
10.48-11.00	O10.10 Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood Maura Massimino , V. Biassoni, R. Miceli, E. Schiavello, M. Warmuth-Metz, P. Modena, F. Giangaspero, F. Spreafico, F. Bach, L. Gandola; Milano (IT)
11.00-11.30	Coffee break
11.30-12.00	Special Lecture Chair: R. Soffietti, Turin (IT) EORTC Brain Tumor Group in perspective W. Wick, Heidelberg (DE)
12.00-13.00	Keynote Lecture Chair: M. Weller, Zurich (CH) Toys are us: where is radiation oncology moving? M. Brada, Liverpool (UK)
13.00	Closing Remarks & Poster Awards Closing Ceremony - from President to President Welcome to EANO XII 2016, Mannheim/Heidelberg, Germany

SIDE MEETINGS

Side Meetings

As per date of printing.

Thursday, October 9, 2014

08.00–15.00 EORTC Meeting

12.15–13.15 EANO Magazine Editorial Board

Room Madrid

Room Bruxelles

Friday, October 10, 2014

13.00–14.00 Committee of Chairs of National Groups

14.15–15.15 GLIOSTRY Study

15.30–16.30 SANO (closed meeting)

17.00–17.30 Meet-the-Industries (closed Meeting)

Room Bruxelles

Saturday, October 11, 2014

12.30–13.15 WFNO Business Meeting

15.00–16.00 Editorial Board NeuroOncology / NeuroOncology Practice

17.00–17.30 AINO Executive Board

Room Bruxelles

Saturday, October 11, 2014


16.00–17.00 General Assembly (**Open to all members**)

Room Londra

SIDE MEETINGS

NOTES

NOTES





Scientific Information

Oral Presentations24

Poster Viewing24 + 25

Poster Topics26

Publication

All presentations (spoken and poster) will be published in the October issue of **NeuroOncology**.

INFORMATION FOR ORAL PRESENTATIONS

Projection and Technical Setting

Please hand in your presentation to the technician in the preview center (room Praga, 1st floor) preferably in the morning of the day of your talk but no later than in the break before the start of the respective session.

The supported data media are: CD, DVD (as Data-storage-medium) and USB-Memory Key. You may want to carry a second key/CD as a back-up in case there is any insoluble technical problem. All needed files - also possible movie files! - have to be on the data media.

The lecture halls are equipped with data projection only (no slides).

The preview center is located in **Room Praga**.

Speaking Time

The chairpersons are asked to pay attention to the exact speaking times to avoid any programme delays. Please make note of the indicated time of your presentation. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

Speaking time has been assigned as follows: 10' + 2' discussion.

INFORMATION FOR POSTER PRESENTATIONS

POSTER VIEWING / SESSIONS (Poster Area –along Nizza glas windowed corridor)

Poster Session I (P01 – P08 & P11 – P13)

Friday, Oct 10, 17.00-18.00

Poster Session II (P09 – P10 & P14 – P18)

Saturday, Oct. 11, 17.00-18.00

Schedule for display, mounting and removal

Poster Viewing 1:

For posters displayed in **poster session 1**, **poster mounting** is possible on **Thursday, Oct. 9, 17.00 -19.00 hrs** and on **Friday, Oct. 10, from 08.00-10.30 hrs**.

Posters will be on **display** until **Friday, Oct. 10, 18.00 hrs**.

Poster removal is possible on **Friday, Oct. 10, from 18.00-18.30 hrs** and **Saturday, Oct. 11, from 08.30-09.00 hrs**. Please note that posters not removed until Oct. 11, 10.00 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

Poster Viewing 2:

For posters displayed in **poster session 2, poster mounting** is possible on **Saturday, Oct. 11, from 10.00-10.30 hrs.** Posters will be on display on Saturday, Oct. 11, until 18.00 hrs. Posters within the poster session 2 will be on **display** on **Saturday, Oct. 11, until 18.00 hrs.**

Poster removal is possible on **Saturday, Oct. 11, 18.00-18.30 hrs.** Please note that posters not removed until Oct. 11, 18.30 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

Poster Board Number

Poster authors have received their poster board number by email. You can also find your poster board number in the abstract book. The poster board will show two numbers, corresponding to the posters shown on Friday (Poster Session 1) and Saturday (Poster Session 2) respectively.

Presence at Posters

In order to enable discussion and interaction with other participants, it is mandatory for you or one of your group members to be present at your poster board during the according poster session (see above for the schedule).

Poster Format

The usable surface on the poster board is **90 cm width x 130 cm height** and posters should be in **portrait format**. Material to mount the posters is provided.

Poster Viewing 1:

Friday, Oct. 10, 2014 from 17.00-18.00 hrs

Poster Viewing 2:

Saturday, Oct. 11, 2014 from 17.00-18.00 hrs

P01	Cell biology and signalling
P02	Immunology and immunotherapy
P03	In vitro / in vivo models
P04	Molecular markers
P05	Pediatric brain tumours
P06	Meningiomas
P07	Spinal cord tumours
P08	Brain and leptomeningeal metastases
P11	Primary central nervous system lymphoma (PCNSL)
P12	New developments in surgery
P13	New developments in radiotherapy

P09	Neurotoxicity and neuroprotection
P10	Paraneoplastic neurological syndromes
P14	Epidemiology
P15	Quality of life
P16	Neuroimaging of brain tumours
P17	Glioblastoma and anaplastic gliomas
P18	Supportive and palliative care

POSTER TOPICS

P01 Cell biology and signalling	P01.01-23
P02 Immunology and immunotherapy	P02.01-07
P03 In vitro / in vivo models	P03.01-09
P04 Molecular markers	P04.01-26
P05 Pediatric brain tumours	P05.01-08
P06 Meningiomas	P06.01-16
P07 Spinal cord tumours	P07.01-06
P08 Brain and leptomeningeal metastases	P08.01-28
P09 Neurotoxicity and neuroprotection	P09.01-04
P10 Paraneoplastic neurological syndromes	P10.01-03
P11 Primary central nervous system lymphoma (PCNSL)	P11.01-10
P12 New developments in surgery	P12.01-14
P13 New developments in radiotherapy	P13.01-26
P14 Epidemiology	P14.01-07
P15 Quality of life	P15.01-17
P16 Neuroimaging of brain tumours	P16.01-35
P17 Glioblastoma and anaplastic gliomas	P17.01-95
P18 Supportive and palliative care	P18.01-10



Corporate Satellite Symposia

Satellite Symposium 1 – **prIME Oncology**

Thursday, October 9, 17.30-19.00 hrs28

Satellite Symposium 2 – **Merck & Co Inc.**

Friday, October 10, 18.00-19.30 hrs.....29

Satellite Symposium 3 – **Mundipharma Italy & Sigma-Tau Pharmaceuticals Inc.**

Saturday, October 11, 12.45-13.15 hrs.....30

Satellite Symposium 4 – **Novocure GmbH**

Saturday, October 11, 18.00-19.00 hrs.....30

Corporate Satellite Symposia

Thursday, October 9, 2014

17.30–19.00 Satellite Symposium 1 – prIME Oncology



Room 500

Advances and Challenges in the Management of Glioblastoma

Chair: *Michael Weller, Zurich (CH); Wolfgang Wick, Heidelberg (DE)*

- | | |
|-------------|---|
| 17.30–17.35 | Welcome and introduction
<i>Michael Weller, Zurich (CH)</i> |
| 17.35–17.40 | Brain Teasers |
| 17.40–17.55 | Current therapeutic options in glioblastoma: Progress or status quo?
<i>James Perry, Toronto (CDN)</i> |
| 17.55–18.00 | Brain Teasers |
| 18.00–18.15 | Expanding role of advanced imaging in the management of glioblastoma
<i>Alexander Radbruch, Heidelberg (DE)</i> |
| 18.15–18.20 | Brain Teasers |
| 18.20–18.35 | Molecular biomarkers beyond MGMT promoter hypermethylation: Hope or hype?
<i>Wolfgang Wick, Heidelberg (DE)</i> |
| 18.35–18.40 | Brain Teasers |
| 18.40–18.55 | Back to the future: Exploring novel research directions
<i>Michael Weller, Zurich (CH)</i> |
| 18.55–19.00 | Q&A |
| 19.00 | Concluding Remarks
<i>Wolfgang Wick, Heidelberg (DE)</i> |

This educational activity is provided by prIME Oncology and supported by F. Hoffmann – La Roche Ltd.



Corporate Satellite Symposia

Friday, October 10, 2014

18.00–19.30 Satellite Symposium 2 – Merck & Co Inc.



Room 500

Educational Objectives:

- Educate participants on recent data of the new treatments for GrII/III Gliomas
- Discuss the role of novel treatment for recurrent gliomas
- Provide insight on novel immunology (check point inhibitors) treatments and development in treatment of gliomas

Chair: *Wolfgang Wick, Heidelberg (DE)*

18.00–18.05 **Opening Remarks**, *Wolfgang Wick, Heidelberg (DE)*

18.05–18.25 **Update On The Treatment Of Newly Diagnosed Grade II/III Gliomas**
Martin van den Bent, Rotterdam (NL)

18.25–18.50 **Options In The Treatment Of Recurrent Gliomas**
Roger Stupp, Zurich (CH)

18.50–19.15 **Active Immunotherapy and Check Point Inhibitors:
where is it going in glioma**
Wolfgang Wick, Heidelberg (DE)

19.15–19.30 **Q&A Panel Discussion**
All Faculty

Corporate Satellite Symposia

Saturday, October 11, 2014

12.45–13.15 Satellite Symposium 3
Mundipharma Italy &
Sigma-Tau Pharmaceuticals Inc.



Room 500

Leptomeningeal disease, 2014 update

Chair: *Maciej M. Mrugala, Seattle (US)*

12.45–12.55 Lymphomatous meningitis- new concepts for a challenging disease
Joachim Baehring, New Haven (US)

12.55–13.05 Neoplastic meningitis - an orphan disease with emerging new strategies
Maciej M. Mrugala, Seattle (US)

Discussion and Q&A session

Saturday, October 11, 2014

18.00–19.00 Satellite Symposium 4 – Novocure GmbH



Room 500

NovoTTF Therapy for Glioblastoma: Learnings from 14 Years of development and clinical research

Chair: *Riccardo Soffietti, Torino (IT)*

18.00–18.12 Reaching therapeutic TTFields intensity inside the brain:
Why does it work?
Pedro Miranda, Lisbon (P)

18.12–18.32 NovoTTF Therapy – an established anti-mitotic device therapy:
New evidence and clinical profile review
Maciej M. Mrugala, Seattle (US)

18.32–18.47 NovoTTF Therapy in everyday practice: Patient selection and practical aspects
Andreas Hottinger, Lausanne (CH)

18.47–19.00 Advancing NovoTTF Therapy, a novel modality of cancer treatment
Eilon Kirson, Tel Aviv (ISR)



Information

Networking Events	33
General Information	35
Registration Fees	39
Sponsor & Exhibitor Listing	40



A more aggressive GBM may be hiding in plain sight

EGFRvIII has been shown to be a marker for more aggressive tumor growth and reduced survival¹⁻³

- The epidermal growth factor variant three (EGFRvIII) mutation is associated with increased growth and more rapid recurrence in GBM¹⁻³
- EGFRvIII may also be a negative predictor of survival³
 - In a study of 196 GBM patients, those who survived beyond the first year and expressed EGFRvIII (n=32) had significantly shorter median overall survival times (1.12 years, $P<0.0001$) compared to those who either expressed EGFR wild type (n=19, 2.02 years) or lacked EGFR (n=38, 2.03 years). This effect remained significant in multivariate analysis after adjustment for other cofactors³

But could EGFRvIII also prove to be an important therapeutic target? Celldex Therapeutics is conducting research on EGFRvIII. Take a closer look at celldex.com.

References: 1. Li et al. *Cancer Res.* 2002;62:3335-3339. 2. Nishikawa R et al. *Proc Natl Acad Sci U S A.* 1994;91:7727-7731. 3. Helmberger AB et al. *Clin Cancer Res.* 2005;11:1462-1466.



©2014 Celldex Therapeutics, Inc. All rights reserved. 5/14

NETWORKING EVENTS

Thursday, October 9, 2014
NETWORKING EVENT
at the Museo dell'Automobile
Start: 19.30 hrs

The Networking Event will take place at the Museo dell'Automobile. Take the opportunity to walk the path of evolution of motor cars throughout the last decades. Spend a nice evening with your colleagues while enjoying fingerfood and drinks.

Free of charge for registered participants, however, due to the limited space available, advance registration (entrance ticket) is mandatory!
Dress Code: Casual

Address:
Museo Nazionale dell'Automobile
"Avv. Giovanni Agnelli"
Corso Unità d'Italia 40
10126 Torino
See map on page 4.



Saturday, October 11, 2014
EANO XI NETWORKING EVENING
at Museo del Risorgimento
Start: 20.00 hrs

The EANO XI Evening will take place in the Aula della Camera Italiana on the second floor of the Museo del Risorgimento. Enjoy a wonderful evening with seated dinner together with your colleagues and friends - make sure not to miss it!


for regular participants:
€ 95,- incl. VAT per person

for students, trainees, residents, nurses:
€ 50,- incl. VAT per person
(at own expense)

Please note that seats are limited and advance registration is mandatory in order to receive a ticket! Limited attendance!
Dress code: formal

Address:
Museo Nazionale del Risorgimento Italiano di Torino
Via Accademia delle Scienze, 5
10123 Torino
See map on page 4.





Precise
Fast
Integrated

RapidArc® for SRS. Simply Revolutionary.



Stereotactic radiosurgery (SRS) is a technique where high doses of radiation are precisely delivered from many directions to a focused target.

RapidArc radiotherapy technology delivers sophisticated SRS treatments faster than previously possible and opens up treatment possibilities for your patients. RapidArc radiosurgery which can be optimized and clinically applied using multiple coplanar and non-coplanar arcs offers a precise and fast alternative to other treatment options.

GENERAL INFORMATION

BADGES

Participants have to collect name badges from the conference registration desk. Since only registered participants will be permitted to attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Accompanying persons and exhibitors will also receive badges to allow access to the respective areas.

Lost badges can be replaced at the registration desk. However, a handling fee of € 30.- will be charged.

CAR PARKING

The Lingotto offers a public parking area for the whole center. Prices for the sections E,F are € 1,50 per hour. Price for 24hrs is about € 13,00-15,00. Please note that the car parking area is unattended.

CERTIFICATE OF ATTENDANCE

Confirmations of attendance will be issued at the registration desk.

CLIMATE

In October, the weather in Turin is generally nice with some rain (average 9 to 17 degrees, 43 % sunny). Turin has an average rainfall of 77 mm in October.

CLOAKROOM AND LUGGAGE

A cloakroom and luggage storage facilities are available in the congress venue.

CME CREDITS

The 11th Meeting of the European Association of NeuroOncology (EANO) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.



The 11th Meeting of the European Association of NeuroOncology (EANO) is designated for a maximum of (or 'for up to') 21 hours of European external CME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

»Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. The rules of the EACCME state that participants are kindly asked feedback (evaluation) form included in the conference bag. It can be returned to the registration desk.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

COFFEE BREAKS

During the session breaks refreshments (coffee, tea and water) will be served free of charge to participants wearing name badges.

CURRENCY

The official currency of Italy is the Euro (€). 1 EURO = 1,32 USD = 0,80 GBP = 137,29 JPY = 1,21 CHF (as per date of printing)

A bank office is located in the 8 GALLERY (the Lingotto mall – first floor of the building)

GENERAL INFORMATION

DRINKING WATER

The tap water in Turin can be used without concern

ELECTRICITY SUPPLY

220-230 V - 50Hz AC, using CEI 23-50, CEI 23-5, some (older) sockets will not accept CEE 7/7 plugs, however in modern installations multiple standard sockets have been used.

EMERGENCY SERVICES

European Emergency Number: 112. (Alternatively, Ambulance – 118; Fire – 115; State Police – 113; Carabinieri – 112; 911 is redirected to 112.)

EXHIBITION OPENING HOURS

Thursday, October 9, 2014 09.00 – 18.00 hrs
Friday, October 10, 2014 09.00 – 18.00 hrs
Saturday, October 11, 2014 09.00 – 18.00 hrs
Sunday, October 12, 2014 08.00 – 13.00 hrs

INSURANCE

In registering for the EANO 2014 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance.

INTERNET

Internet stations as well as WIFI access will be available within the exhibition area.

LANGUAGE

The official language of the congress will be English. Simultaneous translation will only be provided for the Nurse Session on Friday, Oct. 10.

LUNCH AND REFRESHMENTS

During the session breaks refreshments (snacks, tea, and water) will be served free of charge to participants wearing name badges.

MESSAGE BOARD

A message board will be available in the exhibition area.

PHARMACIES

Most pharmacies are open during normal trading hours. The following pharmacies are close to the conference venue: EQUIPARAFARMACIA at 8 Gallery (the mall of Lingotto – first floor of Lingotto Building) - tel. 011 19906879. Farmapiu Torino S.A.S. Della Dott.Sa Calatroni Daniela E C.; Via Genova, 89, Torino OR Farmacia Millefonti Di Giolito Patrizia, Via Genova, 64, Torino

POSTER REMOVAL

Poster Viewing 1:

Poster removal is possible on **Friday, October 10, from 18.00-18.30 hrs** and **Saturday, October 11 from 08.30-09.00 hrs**. Please note that posters not removed until October 11, 10.00 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

Poster Viewing 2:

Poster removal is possible on **Saturday, October 11 18.00-18.30 hrs**. Please note that posters not removed until October 11, 18.30 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

PREVIEW ROOM

The preview center is located in **Room Praga**, 1st floor (see on floorplan, page 6).

PROGRAMME CHANGES – ACCESS TO SESSIONS

The conference organisers reserve a right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser.

PUBLIC TRANSPORTATION

Turin offers a public transportation system with 1 metro, 8 tram lines and 100 bus lines operating 200 km of tramline network and 1200 km of bus network. Also a range of out-of-town buses are available. Tickets for the public transportation have to be bought and punched before entering the train. The following tickets are available:

- Ordinary city ticket: € 1,50 – valid for 90 minutes from first validation on urban lines and on city lines of GGT. Also valid for a metro trip within the 90 minutes validity.
- Ordinary urban + suburban ticket: € 1,70 – valid for 90 minutes on both urban and suburban lines. Also valid for a metro trip within the 90 minutes validity.
- 5-ticket booklet: € 6,50
- 15-ticket booklet: € 17,50
- Daily ticket: € 5,00 – valid for 24 hours from the first validation on urban and suburban lines as well as on subway.
- 2-day ticket / 3-day ticket: € 7,50 / € 10,-

Metro running hours: 06.00-12.00 from Monday to Thursday and from 06.00-13.30 from.

Friday to Saturday; from 08.00-12.00.

Trams and busses: Almost every line begins its journey at 05.00-12.00.

REGISTRATION DESK OPENING HOURS

Thursday, October 9, 2014 **08.00 – 18.00 hrs**

Friday, October 10, 2014 **07.00 – 18.00 hrs**

Saturday, October 11, 2014 **07.30 – 18.00 hrs**

Sunday, October 12, 2014 **07.30 – 12.30 hrs**

SAFETY – CRIME

Visitor safety is generally adequate. As in any other major European city, you can walk everywhere using common sense.

Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:

- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a copy of your passport or any identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference centre.
- In heavily frequented tourist zones, be aware of attempts of scam and pickpocketing.

SHOPS

Most shops downtown are normally open from Monday morning till Saturday evening. E.g. the supermarket Eataly, next to the congress venue, is open daily from 10.00-22.30 hrs.

SMOKING POLICY

The EANO 2014 is officially a “No-smoking-Conference”. Note that smoking is banned in public buildings, restaurants and bars.

STAFF

If you should have any questions, the conference staff recognizable by a yellow badge and a black polo shirt will be pleased to help you.

GENERAL INFORMATION

TAXIS

As in most Italian cities the taxi fares are not cheap. The minimum fare is EUR 3,50. Fares above minimum fare is EUR 1,44 per km, luggage charges EUR 0,50 for each package. Night minimum fares are EUR 6,- for the first km | a waiting charge of EUR 25,70 per hour will be charged.

Prontotaxi – Tel.: +39 (0)115737 / Radiotaxi – Tel.: +39 (0)11/57 30 - 011/33 99

TELEPHONE CALLS

The country code of Italy is 39 and the area code for Turin is 011. If calling a number in Turin from within Italy (including Turin!), dial 011 before the subscriber number.

GMS cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire beforehand or online at your provider which roaming company in Italy offers the cheapest tariffs.

TIPPING

Tipping is quite flexible in Turin as the 'coperto' (cover charge)/service charge is automatically added to the bill. However, if you are happy with the service then tipping the staff is acceptable. Taxi drivers, theatre and cinema usherettes, luggage handlers are also given a token amount as a tip for their services, but you are not compelled to do so.

TOURIST INFORMATION

Torino tourist informations:

- Piazza Carlo Felice (In front of Porta Nuova train station): mon-sun 09.00-18.00
- Via Garibaldi 45/a (Intesa Superflash): mon-sat 13.30-19.00
- Piazza Castello ang. Via Garibaldi: mon-sun 09.00-18.00

Call center

Tel. +39 011 535181 (mon-sun 9.30-12.30, 14.30-18.00). info.torino@turismotorino.org

TRAVELING

The best way to reach the Centro Congressi Lingotto is to use the public transportation system: from the city center and the railway stations of Porta Nuova and Porta Susa take the metro line toward the station "Lingotto" (exit on the right) which is located in walking distance from the main entrance of the congress center.

From the airport: To reach the Centro Congressi Lingotto please use the SADEM Service Bus. This service links the Caselle Turin Airport to the Turin City center by a bus every 15' / 30'. The route includes stops at the railway stations of Porta Nuova and Porta Susa. Ticket Price: 6.50 Euros (add 0.50 Euros on board); for the owners of the Torino + Piemonte Card the price is: 5 Euros. Journey Time: 45-50 minutes. Only those passengers with ordinary ticket SADEM are allowed: all passengers must buy the ticket before boarding and bring it for the entire trip. You can buy the tickets within the airport arrival area. For further information and to have the confirmation of departure hours please contact the SADEM Bus Service by phone from landlines at number 800/801600 or by the number 011/30.00.611 for the mobile phones.

By Car: From the main motorways Piacenza, Pavia, Genova, Savona, Milano, Aosta Frejus e Pinerolo – direction TORINO, continue on the South Ringroad - exit Corso Unità d'Italia then follow signs to Lingotto. From downtown: access to the underground parking sectors – from Via Nizza n. 230 and n. 280 bis.

By Train: Turin's main train stations are Porta Nuova and Porta Susa, just south of the center on Piazza Carlo Felice, which marks the intersection of Turin's two major thoroughfares, Corso Vittorio Emanuele and Via Roma.

By Bus: Turin's main bus terminal is Autostazione Terminal Bus, Corso Inghilterra 3 (near Stazione di Porta Susa). The ticket office is open daily from 7am to noon and 3 to 7pm.

TURIN

Turin is an attractive city located in Northern Italy between the Alps and the Mediterranean sea. Turin was the first Italian capital between 1861 and 1865 and its historical importance is shown by many architectural masterpieces, like the Mole Antonelliana, which is the hallmark of the city and the Reggia di Venaria, a Royal Residency. Moreover, the Egyptian Museum is the second most important in the world.

V.A.T.

The Italian VAT rate is 22%.

REGISTRATION FEES

Onsite registration is possible during the opening hours of the registration desk as follows:

Thursday, October 9, 2014	08.00 – 18.00 hrs
Friday, October 10, 2014	07.00 – 18.00 hrs
Saturday, October 11, 2014	07.30 – 18.00 hrs
Sunday, October 12, 2014	07.30 – 12.30 hrs

Payment received by all fees include VAT	before June 15, 2014 (reduced rate)	between June 15 and August 31, 2014 (normal rate)	after 31 August 2014 and on site
Regular participants/EANO members	EUR 475.–	EUR 560.–	EUR 635.–
Regular participants/Non-members	EUR 745.–	EUR 830.–	EUR 900.–
PhD students and residents, Nurses, Trainees	EUR 245.–	EUR 245.–	EUR 305.–

Important

The reduced registration fee was only applicable, if it was credited to the congress account before the deadline. Registering before the respective deadlines without performing an actual payment is not sufficient to benefit from the reduction.

EANO XI Educational course (Thursday, October 09, 2014)

Registration fee: EUR 200.– incl. VAT

If you wish to attend the Educational course, please note that it is NOT included in the registration fees of EANO 2014. The Educational course is subject to additional registration and costs. The attendance is limited. Please make sure to pre-register well in advance!

EANO XI Networking Event - Museo dell'Automobile (Thursday, October 9, 2014)

Participants no fee, but registration is mandatory

EANO XI Evening - Museo del Risorgimento (Saturday, October 11, 2014)

Regular Participants EUR 95.– incl. VAT

Students, Trainees, Nurses EUR 50.– incl. VAT

What is covered by the registration fee?

Participants: Admission to all scientific sessions, exhibition and networking event, abstract book and programme, coffee breaks.

EANO X Educational course: Admission to courses of your choice, Syllabus, coffee breaks.

Payment of the registration fees:

can be made by:

Cash, Credit Card (Visa, Mastercard, Diners Club), **ATM card**

Cancellations and refunds

Notice of cancellation must have been made in writing, by registered letter or fax, to the Conference Office.

Registration fees will be refunded as follows:


- Written cancellation received:
- before June 15, 2014: 75% refund
 - between June 15 and August 31, 2014: 25% refund
 - after August 31, 2014: no refund

The date of the email or fax ID will be the basis for considering refunds. Please indicate the preferred method of reimbursement (cheque or bank transfer, incl. account number) on your written cancellation. Refunds will be made after the congress.

The European Association of NeuroOncology gratefully acknowledges the support of the following institutions, companies and organizations (as per date of printing):

Sponsors

Platinum Sponsors



MSD



Gold Sponsor

novocure™

Silver Sponsor



Celldex
therapeutics

Other Sponsors



medac
neurosurgery

EXHIBITOR LISTING

The European Association of NeuroOncology gratefully acknowledges the support of the following institutions, companies and organisations (as per date of printing):

Brain Tumour Research
www.braintumourresearch.org

EANS
EANO
www.eano.eu

AINO
www.neuro-oncologia.eu

Elekta
www.elekta.com

EONS
www.cancernurse.eu

Deutsche Hirntumorhilfe e.V.
www.hirntumorhilfe.de

IBTA
www.theibta.org

MagForce AG
www.magforce.com

Novocure
www.novocure.com

Oxford University Press
www.oup.com


Varian Medical Systems International
www.varian.com

Wisepress
www.wisepress.com

FLOORPLAN EXHIBITORS

FLOORPLAN EXHIBITORS

AINO	9
Brain Tumor Research	6
Deutsche Hirntumorhilfe e.V.	8
EANS	7
Elekta	11
EONS	4
IBTA	5
MagForce AG	2
Novocure	1
Oxford University Press	3
Varian Medical Systems International	12
Wisepress	10




As per date of printing.

NOTES

SETON

NOTES

NOTES



Join the Novocure
Satellite Symposium
6:00 PM Saturday, Hall 500

THIS IS WHAT RECURRENT GBM THERAPY CAN LOOK LIKE TODAY



GBM=Glioblastoma

Learn more about the NovoTTF™-100A System
at NovoTTFtherapy.com

**Visit Novocure at EANO
Booth 12**

novocure™

A satellite symposium in conjunction with the
11th European Association of NeuroOncology Conference

ADVANCES AND CHALLENGES IN THE MANAGEMENT OF GLIOBLASTOMA

Thursday, 9 October 2014
17.30-19.00 hrs

Room 500
Centro Congressi Lingotto
Turin, Italy

CO-CHAIRS

Michael Weller, MD
University Hospital of Zürich
Zürich, Switzerland

Wolfgang Wick, MD
University of Heidelberg and
German Cancer Research Center
Heidelberg, Germany

FACULTY

Alexander Radbruch, MD, JD
University of Heidelberg
Heidelberg, Germany

James Perry, MD
Sunnybrook Health Sciences Center
University of Toronto
Toronto, Ontario, Canada

SUPPORT



This educational activity is supported
by F. Hoffmann-La Roche Ltd.

AGENDA

- 17.30 Welcome and introduction
Michael Weller, MD
- 17.35 Brain teasers
- 17.40 Current therapeutic options in glioblastoma:
Progress or status quo?
James Perry, MD
- 17.55 Brain teasers
- 18.00 Expanding role of advanced imaging
in the management of glioblastoma
Alexander Radbruch, MD, JD
- 18.15 Brain teasers
- 18.20 Molecular biomarkers beyond *MGMT*
promoter hypermethylation: Hope or hype?
Wolfgang Wick, MD
- 18.35 Brain teasers
- 18.40 Back to the future: Exploring
novel research directions
Michael Weller, MD
- 18.55 Q&A
- 19.00 Concluding remarks
Wolfgang Wick, MD

REGISTER ONLINE:

www.prIMEoncology.org/glioblastoma_turin